PMID- 29948358
OWN - NLM
STAT- MEDLINE
DCOM- 20190603
LR  - 20190603
IS  - 1573-0646 (Electronic)
IS  - 0167-6997 (Linking)
VI  - 36
IP  - 5
DP  - 2018 Oct
TI  - Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular 
      carcinoma: a prospective study.
PG  - 911-918
LID - 10.1007/s10637-018-0621-x [doi]
AB  - Sorafenib has been widely used to treat unresectable hepatocellular carcinoma 
      (HCC) but most studies have been done in Child-Pugh A (CP-A) patients with 
      well-preserved liver function. We evaluated the overall survival (OS) and 
      tolerance to sorafenib in a large cohort of Child-Pugh B (CP-B) HCC patients as 
      compared to CP-A HCC patients. We prospectively studied 130 patients with 
      advanced HCC who started sorafenib between January 2011 and December 2015. 
      Patients were classified as CP-A (n = 65) or CP-B (n = 65). The average OS for 
      all 130 patients was 10 months. CP-A patients had a median survival rate 
      significantly longer than CP-B patients: 12 months vs. 6 months. The OS found in 
      our group of CP-B patients was 6.5 months, which is higher than that found in 
      most studies done so far. When stratified, our CP-B patients had better OS than 
      ever reported. The dose of the drug was interrupted due to adverse events (AEs) 
      in 38 (29%) of the patients, of whom 20 (30%) were CP-A patients and 18 (28%) 
      were CP-B patients. This real-life cohort of CP-B HCC patients treated with 
      sorafenib had a higher survival than that described in the literature, with a 
      satisfactory safety profile. Despite the high prevalence of severe AEs in CP-B 
      patients, there were fewer treatment interruptions in this group, indicating that 
      Child-Pugh B patients can tolerate treatment and may benefit from sorafenib.
FAU - Leal, Cassia Regina Guedes
AU  - Leal CRG
AUID- ORCID: 0000-0002-9653-8088
AD  - Hospital Federal dos Servidores do Estado, Rua Sacadura Cabral, 178, Saude, Rio 
      de Janeiro, RJ, 20221-903, Brazil. cassia.r.g.leal@gmail.com.
AD  - Universidade Federal Fluminense, Niteroi, Brazil. cassia.r.g.leal@gmail.com.
FAU - Magalhaes, Cristiane
AU  - Magalhaes C
AD  - Instituto Nacional do Cancer (INCA), Rio de Janeiro, Brazil.
FAU - Barbosa, Daniel
AU  - Barbosa D
AD  - Hospital Federal dos Servidores do Estado, Rua Sacadura Cabral, 178, Saude, Rio 
      de Janeiro, RJ, 20221-903, Brazil.
FAU - Aquino, Diogo
AU  - Aquino D
AD  - Hospital Federal dos Servidores do Estado, Rua Sacadura Cabral, 178, Saude, Rio 
      de Janeiro, RJ, 20221-903, Brazil.
FAU - Carvalho, Bernardo
AU  - Carvalho B
AD  - Hospital Federal dos Servidores do Estado, Rua Sacadura Cabral, 178, Saude, Rio 
      de Janeiro, RJ, 20221-903, Brazil.
FAU - Balbi, Elizabeth
AU  - Balbi E
AD  - Hospital Quinta D'Or, Rio de Janeiro, Brazil.
FAU - Pacheco, Lucio
AU  - Pacheco L
AD  - Hospital Quinta D'Or, Rio de Janeiro, Brazil.
FAU - Perez, Renata
AU  - Perez R
AD  - Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
AD  - Instituto D'Or de Pesquisa e Ensino, Rio de Janeiro, Brazil.
FAU - de Tarso Pinto, Paulo
AU  - de Tarso Pinto P
AD  - Hospital Federal dos Servidores do Estado, Rua Sacadura Cabral, 178, Saude, Rio 
      de Janeiro, RJ, 20221-903, Brazil.
FAU - Setubal, Sergio
AU  - Setubal S
AD  - Universidade Federal Fluminense, Niteroi, Brazil.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
DEP - 20180613
PL  - United States
TA  - Invest New Drugs
JT  - Investigational new drugs
JID - 8309330
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (alpha-Fetoproteins)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents/*therapeutic use
MH  - Carcinoma, Hepatocellular/blood/classification/*drug therapy
MH  - Female
MH  - Humans
MH  - Liver Neoplasms/blood/classification/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Sorafenib/*therapeutic use
MH  - Survival Analysis
MH  - alpha-Fetoproteins/analysis
OTO - NOTNLM
OT  - Child-Pugh A
OT  - Child-Pugh B
OT  - Hepatocellular carcinoma
OT  - Sorafenib
EDAT- 2018/06/28 06:00
MHDA- 2019/06/04 06:00
CRDT- 2018/06/28 06:00
PHST- 2018/03/18 00:00 [received]
PHST- 2018/06/07 00:00 [accepted]
PHST- 2018/06/28 06:00 [pubmed]
PHST- 2019/06/04 06:00 [medline]
PHST- 2018/06/28 06:00 [entrez]
AID - 10.1007/s10637-018-0621-x [pii]
AID - 10.1007/s10637-018-0621-x [doi]
PST - ppublish
SO  - Invest New Drugs. 2018 Oct;36(5):911-918. doi: 10.1007/s10637-018-0621-x. Epub 
      2018 Jun 13.